InMed Pharmaceuticals (INM) Enterprise Value (2020 - 2026)

InMed Pharmaceuticals has reported Enterprise Value for 7 years, with the latest figure at -$5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 10.57% year-over-year to -$5.2 million; the trailing twelve-month figure through Mar 2026 stood at -$5.2 million (down 10.57% YoY), and the FY2025 full-year result was -$10.8 million, down 63.07% from the prior year.
• Enterprise Value for Q1 2026 stood at -$5.2 million, up from -$7.0 million in the prior quarter.
• The five-year high for Enterprise Value was -$4.7 million in Q1 2025, with the low at -$11.5 million in Q4 2022.
• Historically, Enterprise Value has averaged -$7.6 million across 5 years, with a median of -$6.8 million in 2023.
• Annual changes were most pronounced in 2024 — Enterprise Value soared 41.29% — and 2025, when it tumbled 66.61%.
• InMed Pharmaceuticals' Enterprise Value stood at -$11.5 million in 2022, then increased by 16.67% to -$9.6 million in 2023, then soared by 41.29% to -$5.6 million in 2024, then fell by 25.23% to -$7.0 million in 2025, then advanced by 25.57% to -$5.2 million in 2026.
• The last three Enterprise Value figures came in at -$5.2 million (Q1 2026), -$7.0 million (Q4 2025), and -$9.4 million (Q3 2025), per Business Quant data.